Giorgianni F, et al. - Given the link of salbutamol, a β₂ agonist, with a reduced risk of Parkinson disease (PD) has been shown in a recent study, however, other mechanisms may explain this apparent link, so, researchers addressed this topic in this study utilizing the United Kingdom Clinical Practice Research Datalink. Between 1995 and 2016, they created a cohort of 2,430,884 patients aged 50 or over. They found 8,604 cases of PD and matched those to controls (n = 86,040), during follow-up, by gender, age, date of cohort entry, and duration of follow-up, following applying a one-year latency time window. A 17% reduced rate of PD was reported in relation to ever use of β₂ agonists vs no use. However, this link was found to be limited to early short-term use. Following more than 2 years of cumulative duration of use, they no longer identified this link. According to the findings, reverse causality is perhaps responsible for the apparent link of β₂ agonists with a reduced risk of PD, rather than a biological influence of these drugs on the risk of PD.